Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.65 61,099 08:00:00
Bid Price Offer Price High Price Low Price Open Price
3.50 3.80 3.65 3.65 3.65
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.39 -1.32 4
Last Trade Time Trade Type Trade Size Trade Price Currency
12:54:38 O 3,200 3.5501 GBX

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
21/10/201908:16N4 Pharma2,354
07/12/201810:53N4 Pharma - Making good drugs better.3,890

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:54:393.553,200113.60O
11:38:593.5510,000355.01O
08:51:543.558,374297.29O
07:18:373.8039,5251,499.97O
07:13:293.7513,000487.50O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
22/10/2019
09:20
N4 Pharma Daily Update: N4 Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 3.65p.
N4 Pharma Plc has a 4 week average price of 3.05p and a 12 week average price of 2.75p.
The 1 year high share price is 15.20p while the 1 year low share price is currently 2.75p.
There are currently 101,462,537 shares in issue and the average daily traded volume is 250,228 shares. The market capitalisation of N4 Pharma Plc is £3,703,382.60.
20/8/2019
08:42
nobbygnome: As I have said before I am not interested in the share price. It is the technology and the interpretation of the science which fascinates me. So you wanted an unsatisfactory result where they messed up one of the dosing groups? Why don't you answer that simple question...
08/8/2019
21:16
nobbygnome: Another curious character. Why am I 'annoyed'? Because the share price went up today? That is of no interest to me as I am neither long nor short. However, like you I am fascinated to see the outcome of the repeat experiments and how Nuvec develops from here.....or not as the case might be. So I will be here for the interim....
07/8/2019
09:28
nobbygnome: Ok here goes. So this is just all IMHO and you should DYOR. And Charlie I have worked in Pharma for 28 years. My main area of knowledge is as a biochemist/immunologist but unusually I got experience of all stages of the drug development process because I followed a product all the way from the bench through on to the market as the scientific expert. That drug is now turning over 1.5 billion Euros.... I will do this as bullet points 1. The current experiments are being done in animals; I suspect mice but I stand to be corrected on that. As we all know mice and men are not the same so the real test will only come when Nuvec goes into humans and they are a long way from doing that. 2. Both the experiments done by UOA with a DNA vaccine and the experiments done by N4P's CROs with a mRNA vaccine failed to get an in vivo response. So it wasn't just one set of experiments where poor results were obtained. This suggests that the whole experimental and manufacturing process is unreliable which could be due to a number of reasons. To think that this unreliability can be solved just by doing one more set of experiments is naive and the chances are an intermediate result will be obtained, which will raise more questions than answers. 3. The current set of experiments are being done with ovalbumin which is an irrelevant molecule. It is used in experimental systems because it is very easy to use. Even if positive results are obtained with this, success with the real more complicated molecules is by no means guaranteed. 4. Overall there are so many red flags here about the science and the company's ability to push the program forward in an expeditious manner. The bottom line is that from what I can tell, this technology is a world away from being a reliable, consistent system which can be licensed to partners. There is a real chance that they will not be able to sort out the issues and it will effectively be worthless. I think previous announcements over many years have been misleading in how far the development of this technology have progressed. This also gives me a trust issue with the management. Clearly if they get a good result in the current tests, I may well modify my view and of course the share price will go up a lot. However, you can see from my points here that I think there is severe doubt over whether that will be the case. I will be very happy to be proved wrong and as I said previously I will be the first to congratulate the company and shareholders in that case.
31/7/2019
19:13
charlie8888: I honestly think that the share price at the moment is irrelevant .what matters is what the price will be in the short future. My guess will be 30 after results then a dip to 20 then a nice steady rise over the next 12 months. But what do I know .
30/7/2019
13:01
charlie8888: If nobby is right then because the share price has not moved half as much as most expected , then most must expect the company to soon be bust.
12/7/2019
12:48
jakleeds: Nothing better on a sunny friday afternoon than an intra-day reversal in N4P share price. The chart looks primed for its next leg up imo. No ramp intended !
12/7/2019
12:12
sbb1x: The share price is obviously being played by a couple of traders.Just need a few more traders to come in and upset the apple cart.
03/2/2018
08:53
nick2412: Hugh, I guess the wording translates as MedImmune / AZ have the right to discuss and seek exclusivity whilst N4P retain the right to name their price. I think it would require a very large initial milestone payment for an exclusive license, or, alternatively, necessitate buying Nuvac outright for a sum that equates in the N4P share price to pounds rather than pence for AZ (or any other company for that matter) to achieve exclusivity. The studiy highlighting the differences between Nuvac and current / other DNA /RNA drug delivery methods should be published this quarter and perhaps before the Japan visit. Existing findings suggest that Nuvac will be in demand so the potential is a)a lucrative exclusive deal with AZ b) multiple licensing deals with different partners c) a bidding war to buy Nuvac outright. Early days but it's looking interesting to say the least.
03/7/2017
18:23
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
18/5/2017
12:50
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
N4P
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191022 19:27:45